Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia

Thomas Burmeister1, Aeint-Steffen Ströh2,3, Britta Kehden2,3

  • 1Department of Hematology, Oncology and Tumor Immunology, CVK, Charité-Universitätsmedizin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. thomas.burmeister@charite.de.

Leukemia
|March 23, 2024
PubMed
Abstract

No abstract available in PubMed .

Related Concept Videos